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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not 
antidepressants are effective for smoking cessation in African American smokers aged 18 and 
older. 
  
Study Design: Review of two randomized controlled trials published in 2002 and 2011 and one 
pilot randomized control trial published in 2011, all English language. 
 
Data Sources: Two randomized, double-blind, controlled trials comparing bupropion to a 
placebo group and one pilot randomized controlled trial comparing varenicline with adherence 
support for smoking cessation to the control without adherence support. All articles were found 
using Medline, PubMed, and OVID. 
 
Outcomes Measured: Smoking cessation was determined on cotinine and/or carbon monoxide 
verified samples; reduction in cigarettes smoked per day based on patient self-report; adverse 
effects of treatment were obtained with use of a prompted checklist containing the 10 most 
common symptoms associated with quitting smoking and smoking cessation pharmacotherapy, 
and with the National Cancer Institute’s Common Toxicity Criteria for Adverse Events. 
 
Results: Cox and Ahluwalia demonstrated that bupropion was effective for smoking cessation 
over seven weeks, however results were inconclusive for long-term abstinence. Nollen reported 
that adherence support was ineffective at promoting smoking abstinence in African American 
smokers utilizing varenicline as a cessation aid.  
 
Conclusions: The results of the randomized controlled trials reviewed demonstrate that the 
antidepressant drug, bupropion, given over seven weeks, was safe and effective for smoking 
cessation in African American light and heavy smokers.  Evidence is inconclusive to support the 
efficacy of bupropion for long-term smoking cessation. In the pilot trial, there was no significant 
difference between the treatment receiving varenicline with adherence support and the control, 
however, there was a significant reduction in cigarettes smoked per day; these results need to be 
interpreted with caution due to limitations in study design being that the sample size was 
insufficient and a control arm receiving placebo was not included in the study. Further studies 
with larger sample sizes are warranted to compare the safety and efficacy of bupropion versus 
varenicline since limited studies exist surrounding non-nicotine replacement smoking cessation 
aids in African American smokers.  
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INTRODUCTION 
In the United States, tobacco use continues to be the primary preventable cause of 
morbidity and mortality for all racial and ethnic groups despite a dramatic decrease in overall 
smoking prevalence.1,2 Of particular concern, African Americans living in the inner city have a 
smoking rate as high as 45% compared to the national average rate of 25%.2 African Americans 
are more likely to attempt to quit smoking in a given year, but have a success rate 34% lower 
than Caucasians.2 Cessation is beneficial for smokers of all ages regardless of the extent of their 
past smoking history. Smoking cessation greatly reduces the risk of developing and prematurely 
dying from smoking-related malignancy and pulmonary, cardiovascular, or cerebrovascular 
disease. 1,3 Additionally, African Americans have a 43-55% higher relative risk of smoking-
attributable lung cancer when compared to Caucasians. This further validates that this population 
is a high-risk group and, thus, a national health care priority.4 
African Americans continue to be significantly underrepresented in smoking cessation 
research despite suffering greater morbidity and mortality attributed to smoking.1 Previous 
research trials investigating smoking cessation aids contained predominately Caucasian moderate 
to heavy smokers as study participants; therefore, results are not particularly generalizable to the 
African American smoking community. African American smokers are more likely to be “light” 
smokers, smoking <10 cigarettes per day, and they tend to smoke high-tar, mentholated 
cigarettes.1 Furthermore, African Americans have been found to have slower rates of nicotine 
metabolism and have higher levels of cotinine (the primary metabolite of nicotine) per cigarette 
smoked when compared to Caucasian smokers.1 These differences, coupled with the increased 
quit attempts with decreased success rates, suggest that with an improved therapeutic aid, 
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successful smoking cessation can be obtained. This would in turn yield to a decrease in the 
degree of disproportional disease-burden attributed to smoking experienced by this population. 
According to the most recent data, in 2010, 201,144 people in the United States were 
diagnosed with lung cancer.5 Between 2000-2004, cigarette smoking in the United States cost 
over $193 billion, with $97 billion in lost productivity and $96 billion in health care 
expenditures.6 Multiple therapeutic approaches exist to aid smoking cessation, each with a 
different mechanism of action. One of the most common therapies is nicotine replacement 
therapy (NRT) available in the form of gums, patches, lozenges, and electronic cigarettes.7 
Additional smoking cessation aids include non-nicotine pharmacotherapeutics such as 
antidepressant medications, like bupropion, which is believed to have dopaminergic and 
noradrenergic activity, or partial nicotine agonists, like varenicline. Varenicline is often 
associated with antidepressants due to its mood-altering capabilities, however it is not 
pharmacologically classified as an antidepressant despite common misperception. Alternative 
treatments for smoking cessation include acupuncture, hypnosis, aversive therapy, and 
behavioral counseling.7 
While there are many treatment options available to aid smoking cessation, the efficacy 
and tolerability of antidepressant drugs for smoking cessation in African Americans is 
unknown.4,2 This paper evaluates two randomized, double-blind, placebo-controlled trials that 
examine the efficacy and tolerability of the antidepressant, bupropion, in the treatment of 
smoking cessation; additionally, this paper analyzes a pilot study that investigated the use of 
varenicline and adherence support for smoking cessation in African American smokers. This 
literature review consists of the best available evidence given the population of interest and the 
topic in the clinical question. 
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OBJECTIVE 
The objective of this selective EBM review is to determine whether or not the use of 
antidepressants are effective for smoking cessation in African American smokers aged 18 and 
older. 
METHODS 
Specific criteria was designated for the selection of the three trials used in this paper.  
Criteria for population included African American smokers >18 years old that were interested in 
quitting smoking. The types of studies included two RCTs (randomized controlled trials) and a 
pilot RCT. The intervention studied in the two RCTs was bupropion SR in the standardized 
dosing schedule: 150 mg QD for 3 days, followed with 150mg BID for 7 weeks.1,2 In the pilot 
trial, the intervention studied was varenicline in the standardized dosing schedule: 0.5mg QD for 
3 days, followed with 0.5mg BID for 4 days, followed by 1 mg BID for 11 weeks with adherence 
support for continued encouragement regarding the use of pharmacotherapy.4  For the RCTs, the 
treatment group receiving the bupropion was compared to the control group receiving a visually-
matched placebo while in the pilot trial, the treatment group receiving varenicline with adherence 
support was compared to the control group receiving varenicline with standard care.  Measured 
outcomes that were being utilized in this review included biochemically-verified smoking 
cessation based on cotinine and/or carbon monoxide verified samples, reduction in cigarettes per 
day (cpd) based on patient self-report, and adverse events. 
The study by Cox et al1 was a randomized, double-blind placebo-controlled trial. The 540 
study participants were all African American light smokers (smoked <10 cpd) and were 
randomly assigned to receive bupropion SR or placebo for a treatment period of 7 weeks with up 
to six health education counseling sessions.  
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The study by Ahluwalia2 was a randomized, double-blind placebo-controlled study that 
involved 600 African American moderate to heavy smokers (smoked >10 cpd). Participants were 
randomly assigned to receive bupropion SR or placebo for a treatment period of 7 weeks with 
brief motivational counseling.  
In the pilot study by Nollen et al4, all 72 participants were randomized into two groups 
and received a one-month supply of varenicline dispensed in a monthly pillbox in addition to 
verbal instruction on how to properly take the medication. All participants met with a study 
counselor to gain information regarding the risks of continued smoking, the benefits of cessation, 
management strategies for coping with withdrawal and cravings, and assistance in developing a 
quit plan (standard care).4 The treatment group (adherence support) received five additional 
counseling sessions on Days 8, 12, 20, 30, and 60 to promote the participants’ motivation to 
adhere to their medication as prescribed. These participants were also counseled on behavioral 
techniques to manage the expected adverse events associated with varenicline therapy.4  
Keywords used in literature search were “smoking cessation”, “African American”, 
“black” and “bupropion”. All articles were published in peer-reviewed journals in the English 
language.  Literature searches were conducted via Medline, PubMed, and OVID and articles 
were selected based on their relevance to the clinical question and inclusion of patient-oriented 
outcomes (smoking cessation, reduction in cigarettes smoked per day, adverse events).  Studies 
included in the search were randomized controlled trials published after 1996 that included 
patient-oriented outcomes, and a study population of African American adult smokers >18 years 
of age.  Exclusion criteria consisted of studies that the patient population was <18 years of age 
and non-African American.  The statistics reported in these studies included mean change from 
baseline, 95% confidence interval (CI), and p-value.   
Myskowski, Antidepressants & AA Smoking        
 
5
Table 1- Demographics & Characteristics of included studies 
STUDY TYPE PTS 
(n) 
AGE INCLUSION 
CRITERIA 
EXCLUSION CRITERIA W/D INTERVE
NTIONS 
 
Ahluwalia
2, 2002 
 
Randomiz
ed, 
double-
blind, 
placebo-
controlled 
trial 
 
600 
 
Mean 
= 44 
Self-identified 
"African American 
or black;" > 18 
years old; >10 
cigarettes per day; 
interested in 
quitting in next 30 
days; spoke 
English; has a 
permanent home 
address with 
working telephone.  
Contraindication for bupropion SR 
(predisposition to seizures, excessive 
alcohol use, bulimia or anorexia 
nervosa, current use of bupropion or 
psychoactive medication, pregnant, 
use of other tobacco forms or NRT in 
past 30 days); in drug treatment 
during past 6 months; or being 
treated for depression. 
 
189 
at 
wk 
26 
 
Bupropion 
SR; 
dosage: 
150 mg QD 
x3 days, 
then 150mg 
BID x7 
weeks 
 
 
Cox et al1, 
2012. 
 
 
Randomiz
ed, 
double-
blind, 
placebo-
controlled 
trial  
 
 
540 
 
 
Mean 
= 46 
Self-identified 
African American, 
aged  >18 years, 
interested in 
quitting smoking, 
smoked <10 CPD x 
<2 years, smoked 
on >25 days in past 
month, smoked > 3 
years; had a home 
address and 
functioning 
telephone; willing 
to attend scheduled 
study visits and to 
provide biological 
samples for genetic 
analyses related to 
nicotine and 
bupropion 
metabolism.  
Current use of bupropion; use of 
psychoactive medications, NRT, 
fluoxetine, clonidine, buspirone, or 
doxepin in past 30 days; hx of 
alcohol or substance abuse within 
past year; current drinking of >14 
alcoholic drinks Q week and/or 
drinking >5 drinks on one occasion 
>2 times in past month; hx of 
seizures or head trauma; hx of 
bulimia or anorexia nervosa; current 
pregnancy (verified by OTC test kit) 
or contemplating pregnancy; breast 
feeding; MI in past 30 days; use of 
other tobacco forms in past 30 days; 
use of opiates, cocaine, or stimulants; 
or diabetes treated c oral 
hypoglycemics or insulin; intention 
to move from Kansas City region in 
next 12 months; or presence of 
another study participant in 
household.  
 
161 
at 
wk 
26 
 
Bupropion 
SR; 
dosage: 
150 mg QD 
x3 days, 
then 150mg 
BID x7 
weeks  
 
Nollen et 
al4, 2011 
 
Pilot study 
 
72 
 
Mean
= 
46.8 
 
African American; 
≥18 years of age; 
smoking >10 cpd; 
wanting to quit, 
and willing to take 
varenicline 
 
Planning to move from the area 
within 3 months or had 
contraindications to use of 
varenicline (CV event in month prior 
to enrollment; renal impairment, 
taking insulin for diabetes but 
unwilling to closely monitor BS); or 
hx of clinically significant allergic 
reactions to varenicline; MDD in 
past year requiring tx; hx of alcohol 
or drug dependency in past year; hx 
of psychosis, panic disorder; bipolar 
disorder or any eating disorders; or 
current breastfeeding, pregnancy or 
plan to get pregnant in next 3 months 
 
12, 
15, 
11 at 
Mon 
1, 2, 
and 
3 
 
Adherence 
support 
(single 
counseling 
session 
focused on 
making a 
quit plan & 
5 additional 
counseling 
sessions to 
encourage 
medication 
use) with 
varenicline. 
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OUTCOMES MEASURED 
Outcomes measured were those of patient-oriented evidence that matters (POEMs). 
Smoking abstinence was measured via patient self-report and biochemically confirmed through 
salivary cotinine and expired carbon monoxide verified samples. Reduction of cigarettes smoked 
per day was self-reported. Medication adverse events were measured through a prompted 
questionnaire containing the top ten common symptoms associated with quitting smoking and 
smoking cessation pharmacotherapy (Nollen et al4), self-report (Ahluwalia2) and via the National 
Cancer Institute’s Common Toxicity Criteria for Adverse Events with Grade >3 indicating a 
serious adverse event analyzed using Pearson X2 test (Cox et al1).  
 
RESULTS 
The two randomized, controlled trials compared bupropion to placebo, and the pilot 
randomized, controlled trial compared varenicline and adherence support to varenicline and 
standard care. 
The study by Cox et al1 found at week 3, the bupropion group had significantly higher 
levels of cotinine-verified 7-day point prevalence abstinence versus the placebo (21.5% vs 9.6%, 
OR=1.39, 95% CI= 1.56-4.22, p <.001). At the end of the medication phase, week 7, the 
treatment group was again found to have significantly higher cotinine-verified smoking 
abstinence over the placebo (23.7% vs 9.6%, OR= 2.92, 95%CI= 1.78-4.77, p<.001). This study 
found no statistically significant differences between bupropion SR and placebo at week 26 
(13.3% vs 10.0%, OR= 1.39, 95%CI=0.82-2.35, p=.23).1 Overall, this study concluded that 
bupropion SR was effective for short-term smoking abstinence in African American light 
smokers. Particular efficacy was notable at initial abstinence early in the treatment phase, during 
Myskowski, Antidepressants & AA Smoking        
 
7
week 3, and following the completion of the medication phase at week 7, but not in achieving 
long-term smoking abstinence at week 26.  
The study by Cox et al1 assessed the prevalence of adverse events at week 3 by utilizing 
the National Cancer Institute’s Common Toxicity Criteria for Adverse Events with Grade >3 
indicating serious adverse events. The incidence and severity of adverse events in the 
intervention group were similar to those seen in the placebo group; therefore, no significant 
difference was reported between bupropion SR and the placebo (32.6% vs 28.5%, p> .05 for all 
grades).1 
The study by Ahluwalia2 determined that bupropion SR was effective for smoking 
cessation versus placebo at week 7 of the medication phase (36.0% vs 19.0%, mean difference of 
17.0%, 95%CI=9.7-24.4, p<.001) and this progress was maintained over 26 weeks (21.0% vs 
13.7%, p=.02). For analysis of the safety of treatment, adverse events were reported through 
week 6. The treatment group reported significantly more problems sleeping (29.3% vs 20.7%, 
p=.02 by 2-tailed Fisher exact test). All other adverse events were not deemed significant in this 
study. Most commonly reported adverse events included “problems sleeping” and “dry mouth.”2 
The study by Nollen et al4 reported that there were no significant differences in smoking 
abstinence rates or reduction in cigarettes smoked per day between the treatment group, 
medication adherence support, and the control group, standard care. At Month 3, cotinine-
verified (<20 ng/ml) smoking abstinence was 23.6% (n=17). Among the remaining participants 
that failed to reach abstinence, there was a significant reduction in cigarettes smoked per day 
(cpd). At baseline, participants smoked 16.1 cpd (SD=5.6) and at Month 3, reduced to 4.5 cpd 
(SD=5.3), for a mean decrease of 12.2 cpd (SD= 6.5; p< .0001).4 To summarize these results, the 
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Nollen et al study demonstrated that adherence support was ineffective at promoting smoking 
abstinence in African American smokers utilizing varenicline as a cessation aid. 
In this pilot study, there were no significant relationships established between adverse 
events, medication adherence, or smoking abstinence (p> .05). Study participants reported an 
average of 2.9 (SD=1.8) adverse events on a prompted checklist. These adverse events were 
attributed to the use of varenicline over the duration of the 3-month treatment phase. The highest 
reported adverse events were abnormal dreams (86.0%), nausea (77.0%), and gas (63.2%).4 
 
Table 2. Efficacy of bupropion drugs for smoking cessation 6 weeks after quit date 
Study CER EER RRR (EER-CER/CER) ABI (EER-CER) NNT (1/ABI) p-value 
Cox et al1 0.096 0.237 0.1469 0.14 8 <0.05 
Ahluwalia2 0.19 0.36 0.8947 0.17 6 <0.05 
RRR= Relative Risk Reduction; ABI= Absolute Benefit Increase; NNT= Numbers Needed to Treat;   
CER= Control Event Rate; EER= Experimental Event Rate 
 
Table 2 displays the treatment effects of the studies. ABI shows the increase in successful 
smoking cessation in the bupropion group compared to the placebo group. RRR determines the 
effectiveness of bupropion therapy when compared to the placebo.  NNT reports the number of 
patients that need to be treated with bupropion to produce one good outcome (i.e. smoking 
cessation).  
 
Table 3. Safety of bupropion in the treatment of smoking cessation 
Study CER EER RRI  (EER-CER/CER) ARI (EER-CER) NNH (1/ARI) p-value 
Cox et al1 0.285 0.326 0.1439 0.041 25 p>.05 
Ahluwalia2 0.207 0.293 0.4155 0.086 12 .02 
RRI= Relative Risk Increase; ARI=Absolute Risk Increase; NNH= Numbers Needed to Harm; 
CER= Control Event Rate; EER= Experimental Event Rate  
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Table 3 displays the safety of bupropion therapy.  RRI determines the safety of bupropion 
therapy and also the likelihood of experiencing an adverse event during therapy.  ARI shows the 
increase in amount of adverse events in the bupropion group compared to the placebo group.  
NNH reports the number of patients that need to be treated with bupropion to cause an adverse 
event; 12-25 patients need to be treated to get one adverse event.     
 
DISCUSSION 
This literature review investigated the safety and efficacy of antidepressants for smoking 
cessation in African American smokers >18 years of age. Evidence from the studies by Cox et 
al1 and Ahluwalia2 studies showed that the antidepressant, bupropion, was safe and effective for 
smoking cessation through 7 weeks of medication therapy in both light and heavy African 
American smokers. Evidence was conflicting, and therefore inconclusive, about successful long-
term cessation at week 26.  
Limitations were present in each study that affect their validity and generalizability to the 
clinical question of concern. The greatest limitation for this literature review is the scant amount 
of RCTs previously conducted studying the population of interest. This dramatically narrowed 
the sources available for reference data. Furthermore, the study conducted by Cox et al1 is 
generalizable to light smokers, whereas the study by Ahluwalia2 is specific for heavy smokers. 
Additionally, the study by Nollen et al4 was a pilot study that had a very small sample size of 72 
participants, therefore the results must be interpreted with caution. This study also did not 
include a placebo to adequately measure the efficacy or safety of varenicline. 
The Nollen et al4 study was a pilot trial that investigated adherence support with use of 
varenicline in African American smokers. Varenicline is not pharmacologically classified as an 
Myskowski, Antidepressants & AA Smoking        
 
10
antidepressant medication; it is classified as a partial nicotine agonist that additionally stimulates 
dopamine activity. Bupropion is classified as an antidepressant medication that functions as a 
dopamine-reuptake inhibitor. Although both of these pharmacologic smoking cessations aids 
affect the dopamine pathway and have mood-altering capabilities, they exert very different 
mechanisms of action. Both medications are first-line non-nicotine replacement therapies often 
prescribed as smoking cessation aids. Because limited studies exist in the population at question 
and the common fallacy of varenicline as an antidepressant medication, this pilot study was 
included in this literature review.  
Bupropion is believed to have both dopaminergic and noradrenergic activity. One of the 
most serious adverse events of therapy is lowering of the seizure threshold. A Black Box 
warning has been issued for serious neuropsychiatric events including depression, suicidal 
thoughts and suicide.8 Serious hypersensitivity reactions have been reported with bupropion use. 
These side effects are very rarely seen in the treatment of smoking cessation. In general, side 
effects are minor: CNS stimulation (restlessness, anxiety, insomnia), anorexia, cognitive 
impairment, seizures, weight loss, and sexual dysfunction.8 Bupropion is contraindicated in 
patients who have a history of seizure disorder, anorexia/bulimia, and patients undergoing abrupt 
discontinuation of ethanol or sedatives including benzodiazepines. 8 
Varenicline has a dual mechanism of action. As a partial nicotine receptor agonist, it 
reduces nicotine withdrawal by plugging into the alpha 4, beta 2 nicotinic receptors of the brain.9 
If the patient continues to smoke, the nicotine in the cigarette is unable to reach the receptor 
since it is blocked by the drug. This removes the feel good, rewarding sensation that the patient 
typically experiences from smoking a cigarette. Varenicline, like bupropion, has a Black Box 
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warning for neuropsychiatric effects including depression, suicidal thoughts and suicide. 
Additional side effects include CNS depression, hypersensitivity reactions, and nausea.9 
 
CONCLUSION  
The studies reviewed collectively are inconclusive regarding safety and efficacy of 
antidepressants for smoking cessation in African American adult smokers. Although there was 
no difference in smoking cessation with adherence support, the pilot study that examined 
varenicline showed significant reduction in cigarettes smoked per day. This may be promising 
for discovering successful methods to help African American smokers. Additional methods and 
combinations of therapeutic modalities need to be explored that can compliment or enhance the 
effects of varenicline. Future study is necessary to evaluate the efficacy of bupropion versus 
varenicline to determine which non-nicotine replacement pharmacotherapy is better able to assist 
this population in achieving smoking abstinence. Additionally, further trials are warranted that 
compare varenicline to a placebo in African American smokers to better assess adverse events 
attributed to therapy before routine use can be recommended.  
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